Experienced in Myelodysplastic Syndrome (MDS)

Sabine Brechignac

Bordeaux, FR 
Experienced in Myelodysplastic Syndrome (MDS)
Bordeaux, FR 
OverviewLocationsClinical Research

Overview

Sabine Brechignac practices in Bordeaux, France. Ms. Brechignac is rated as an Experienced expert by MediFind in the treatment of Myelodysplastic Syndrome (MDS). Her top areas of expertise are Multiple Myeloma, Myelodysplastic Syndrome (MDS), Leukemia, Chronic Myelomonocytic Leukemia (CMML), and Bone Marrow Transplant.

Her clinical research consists of co-authoring 29 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles and participated in 1 clinical trial in the study of Myelodysplastic Syndrome (MDS).

Gender
Female

Locations

Bordeaux, France
Other Locations
Bobigny, France
Nancy, France
Toulouse, France
Amiens, France
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Enrollment Status: Completed
Publish Date: November 24, 2025
Intervention Type: Procedure, Drug
Study Drug: Pomalidomide+Cyclophosphamide+Dexamethasone
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Enrollment Status: Terminated
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drugs: SY-1425+Azacitidine, Azacitidine
Study Phase: Phase 3
View 1 Less Clinical Trial

29 Total Publications

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.
Journal: Blood
Published: May 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Brechignac's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile